Cargando…

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer

AIMS: Atezolizumab improved disease-free survival (DFS) versus best supportive care (BSC) as adjuvant treatment following resection and platinum-based chemotherapy for stage II–IIIA PD-L1+ NSCLC in IMpower010. MATERIALS & METHODS: This cost–effectiveness study evaluated atezolizumab versus BSC (...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Millie, Ogale, Sarika, Jovanoski, Nick, Johnson, Ann, Nguyen, Caroline, Bhagwakar, Jan, Lee, Janet S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334222/
https://www.ncbi.nlm.nih.gov/pubmed/37021770
http://dx.doi.org/10.2217/imt-2022-0311
Descripción
Sumario:AIMS: Atezolizumab improved disease-free survival (DFS) versus best supportive care (BSC) as adjuvant treatment following resection and platinum-based chemotherapy for stage II–IIIA PD-L1+ NSCLC in IMpower010. MATERIALS & METHODS: This cost–effectiveness study evaluated atezolizumab versus BSC (US commercial payer perspective) using a Markov model with DFS, locoregional recurrence, first- and second-line metastatic recurrence and death health states, and a lifetime time horizon with 3% annual discounting. RESULTS: Atezolizumab provided 1.045 additional quality-adjusted life-years (QALY) at an incremental cost of $48,956, yielding an incremental cost–effectiveness ratio of $46,859/QALY. Scenario analysis showed similar findings in a Medicare population ($48,512/QALY). CONCLUSION: At a willingness-to-pay threshold of $150,000/QALY and an incremental cost–effectiveness ratio of $46,859/QALY, atezolizumab is cost-effective versus BSC for adjuvant NSCLC treatment.